Hausheer; Frederick H

Patent Applications and Registrations

Patent applications and USPTO patent grants for Hausheer; Frederick H.The latest application filed is for "increasing cancer patient survival time by administration of dithio-containing compounds".

Company Profile

0.41.37

Hausheer; Frederick H - Fair Oaks Ranch TX
Hausheer; Frederick H. - San Antonio TX
Hausheer; Frederick H. - Fair Oaks Ranch TX
Hausheer; Frederick H. - Boerne TX US

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Administration of karenitecin for the treatment of platinum and/or taxane chemotherapy-resistant or -refractory advanced ovarian cancer Grant 10,413,538 - Hausheer Sept	2019-09-17
Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds App 20180369173 - Hausheer; Frederick H.	2018-12-27
Contemporaneous, Heterogeneously-oriented, Multi-targeted Therapeutic Modification And/or Modulation Of Disease By Administration Of Sulfur-containing, Amino Acid-specific Small Molecules App 20170007561 - Hausheer; Frederick H.	2017-01-12
Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds App 20160287540 - Hausheer; Frederick H.	2016-10-06
Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds App 20160287539 - Hausheer; Frederick H.	2016-10-06
Compositions and methods of use of compounds to increase cancer patient survival time Grant 9,320,760 - Hausheer April 26, 2	2016-04-26
Administration Of Karenitecin For The Treatment Of Advanced Ovarian Cancer, Including Chemotherapy-resistant And/or The Mucinous Adenocarcinoma Sub-types App 20160038519 - Hausheer; Frederick H.	2016-02-11
Increasing cancer patient survival time by administration of dithio-containing compounds Grant 9,023,805 - Hausheer May 5, 2	2015-05-05
Methods For The Total Chemical Synthesis Of Enantiomerically-pure 7-(2'-trimethylsilyl) Ethyl Camptothecin App 20140135499 - Chen; Xinghai ; et al.	2014-05-15
Methods for the total chemical synthesis of enantiomerically-pure 7-(2'-trimethylsilyl)ethyl camptothecin Grant 8,722,886 - Chen , et al. May 13, 2	2014-05-13
Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity Grant 8,710,095 - Hausheer April 29, 2	2014-04-29
Germanium-containing camptothecin analogues App 20140073793 - Chen; Xinghai ; et al.	2014-03-13
Deuterated analogs of (4S)-4-ethyl-4-hydroxy-11-[2- (trimethylsilyl)ethyl]-1H-pyrano[3', 4':6,7] indolizino [1,2-b]quinoline-3,14(4H, 12H)-dione and methods of use thereof Grant 8,569,265 - Chen , et al. October 29, 2	2013-10-29
Deuterated analogs of (4S)-4-Ethyl-4-hydroxy-11-[2- (trimethylsilyl)ethyl]-1H-pyrano[3', 4':6,7] indolizino [1,2-b]quinoline-3,14(4H, 12H)-dione and methods of use thereof App 20120282261 - Chen; Xinghai ; et al.	2012-11-08
Chemoprotective methods Grant 8,143,236 - Hausheer March 27, 2	2012-03-27
Increasing cancer patient survival time by administration of dithio-containing compounds App 20120070404 - Hausheer; Frederick H.	2012-03-22
Chemoprotective methods and compositions Grant 8,026,227 - Hausheer September 27, 2	2011-09-27
Compounds and methods for reducing undesired toxicity of chemotherapeutic agents Grant 7,829,117 - Hausheer , et al. November 9, 2	2010-11-09
Compounds and methods for reducing undesired toxicity of chemotherapeutic agents Grant 7,829,541 - Hausheer , et al. November 9, 2	2010-11-09
Compounds and methods for reducing undesired toxicity of chemotherapeutic agents Grant 7,829,538 - Hausheer , et al. November 9, 2	2010-11-09
Compounds and methods for reducing undesired toxicity of chemotherapeutic agents Grant 7,829,540 - Hausheer , et al. November 9, 2	2010-11-09
Compounds and methods for reducing undesired toxicity of chemotherapeutic agents Grant 7,829,539 - Hausheer , et al. November 9, 2	2010-11-09
Monoazole ligand platinum analogs Grant 7,759,488 - Xiao , et al. July 20, 2	2010-07-20
Camptothecin-analog with a novel, "flipped" lactone-stable, E-ring and methods for making and using same Grant 7,687,487 - Hausheer March 30, 2	2010-03-30
Compositions and methods of use of compounds to increase cancer patient survival time App 20090232827 - Hausheer; Frederick H.	2009-09-17
Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions App 20090232906 - Hausheer; Frederick H.	2009-09-17
Platinum complexes with mononitrile-containing ligands Grant 7,569,606 - Xiao , et al. August 4, 2	2009-08-04
Compounds and methods for reducing undesired toxicity of chemotherapeutic agents App 20090111735 - Hausheer; Frederick H. ; et al.	2009-04-30
Camptothecin-analog with a novel, "flipped" lactone-stable, E-ring and methods for making and using same App 20080261919 - Hausheer; Frederick H.	2008-10-23
Chemoprotective methods and compositions App 20080193498 - Hausheer; Frederick H.	2008-08-14
Compounds and methods for reducing undesired toxicity of chemotherapeutic agents App 20080161525 - Hausheer; Frederick H. ; et al.	2008-07-03
Compounds and methods for reducing undesired toxicity of chemotherapeutic agents App 20080161414 - Hausheer; Frederick H. ; et al.	2008-07-03
Compounds and methods for reducing undesired toxicity of chemotherapeutic agents App 20080161603 - Hausheer; Frederick H. ; et al.	2008-07-03
Compounds and methods for reducing undesired toxicity of chemotherapeutic agents App 20080161416 - Hausheer; Frederick H. ; et al.	2008-07-03
Compounds and methods for reducing undesired toxicity of chemotherapeutic agents App 20080161415 - Hausheer; Frederick H. ; et al.	2008-07-03
Anti-cancer activity augmentation compounds and formulations and methods of use thereof App 20070219268 - Hausheer; Frederick H.	2007-09-20
Monoimine ligand platinum analogs Grant 7,268,244 - Hausheer , et al. September 11, 2	2007-09-11
Platinum complexes with mononitrile-containing ligands App 20070173485 - Xiao; Zejun ; et al.	2007-07-26
Platinum complexes with mononitrile-containing ligands Grant 7,238,823 - Xiao , et al. July 3, 2	2007-07-03
Method of treating patients undergoing kidney dialysis Grant 7,235,589 - Hausheer June 26, 2	2007-06-26
Chemoprotective methods and compositions App 20070135519 - Hausheer; Frederick H.	2007-06-14
Method for treating patients for radiation exposure Grant 7,176,192 - Hausheer February 13, 2	2007-02-13
Platinum complexes with mononitrile-containing ligands App 20070004798 - Xiao; Zejun ; et al.	2007-01-04
Monoimine ligand platinum analogs App 20070004697 - Hausheer; Frederick H. ; et al.	2007-01-04
Monoazole ligand platinum analogs App 20070004696 - Xiao; Zejun ; et al.	2007-01-04
Pharmaceutical formulations of camptothecins and process for making same App 20060094692 - Hausheer; Frederick H. ; et al.	2006-05-04
Method of treatment for or protection against lymphedema App 20060063742 - Hausheer; Frederick H.	2006-03-23
Method of treating patients undergoing kidney dialysis App 20060063744 - Hausheer; Frederick H.	2006-03-23
Compounds and methods for reducing undesired toxicity of chemotherapeutic agents App 20050256055 - Hausheer, Frederick H. ; et al.	2005-11-17
Method of protecing against tissue extra vasation injury App 20040152774 - Hausheer, Frederick H.	2004-08-05
Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity App 20030203960 - Hausheer, Frederick H.	2003-10-30
Method For Treating Cancer Having Greater Efficacy And Reduced Adverse Effects App 20030133994 - Hausheer, Frederick H.	2003-07-17
Method for treating patients for radiation exposure App 20030092681 - Hausheer, Frederick H.	2003-05-15
Formulations and methods of reducing toxicity of antineoplastic agents Grant 6,066,668 - Hausheer , et al. May 23, 2	2000-05-23
Highly lipophilic Camptothecin derivatives Grant 6,057,303 - Haridas , et al. May 2, 2	2000-05-02
Formulations and methods of reducing toxicity of antineoplastic agents Grant 6,057,361 - Hausheer , et al. May 2, 2	2000-05-02
Formulations and methods of reducing toxicity of antineoplastic agents Grant 6,040,312 - Hausheer , et al. March 21, 2	2000-03-21
Formulations and methods of reducing toxicity of antineoplastic agents Grant 6,040,294 - Hausheer , et al. March 21, 2	2000-03-21
Formulations and methods of reducing toxicity of antineoplastic agents Grant 5,919,816 - Hausheer , et al. July 6, 1	1999-07-06
Highly lipophilic camptothecin derivatives Grant 5,910,491 - Hausheer , et al. June 8, 1	1999-06-08
Formulations and compositions of poorly water soluble camptothecin derivatives Grant 5,900,419 - Hausheer , et al. May 4, 1	1999-05-04
Formulations and compositions of poorly water soluble camptothecin derivatives Grant 5,859,022 - Hausheer , et al. January 12, 1	1999-01-12
Formulations and compositions of poorly water soluble camptothecin derivatives Grant 5,726,181 - Hausheer , et al. March 10, 1	1998-03-10
Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof Grant 5,674,873 - Hausheer , et al. October 7, 1	1997-10-07
Nuclease resistant compounds Grant 5,567,810 - Weis , et al. October 22, 1	1996-10-22
11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof Grant 5,468,754 - Hausheer , et al. November 21, 1	1995-11-21
Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof Grant 5,447,936 - Hausheer , et al. September 5, 1	1995-09-05
Exonuclease resistant terminally substituted oligonucleotides Grant 5,245,022 - Weis , et al. September 14, 1	1993-09-14
Process of linking nucleosides with a siloxane bridge Grant 5,214,134 - Weis , et al. May 25, 1	1993-05-25

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.